Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CG Oncology (CGON) EBIT Margin (2023 - 2025)

CG Oncology (CGON) has disclosed EBIT Margin for 3 consecutive years, with 2097.33% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBIT Margin rose 624675.0% year-over-year to 2097.33%, compared with a TTM value of 4722.13% through Dec 2025, up 534512.0%, and an annual FY2025 reading of 4722.13%, up 534512.0% over the prior year.
  • EBIT Margin was 2097.33% for Q4 2025 at CG Oncology, up from 3068.97% in the prior quarter.
  • Across five years, EBIT Margin topped out at 2097.33% in Q4 2025 and bottomed at 1935500.0% in Q4 2023.
  • Average EBIT Margin over 3 years is 228460.13%, with a median of 15817.53% recorded in 2024.
  • The sharpest move saw EBIT Margin soared 192715592bps in 2024, then plummeted -7691409bps in 2025.
  • Year by year, EBIT Margin stood at 1935500.0% in 2023, then skyrocketed by 100bps to 8344.08% in 2024, then skyrocketed by 75bps to 2097.33% in 2025.
  • Business Quant data shows EBIT Margin for CGON at 2097.33% in Q4 2025, 3068.97% in Q3 2025, and 81161.54% in Q1 2025.